These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8500783)

  • 1. Dopamine agonists in Parkinson's disease: a look at apomorphine.
    Lees AJ
    Fundam Clin Pharmacol; 1993; 7(3-4):121-8. PubMed ID: 8500783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D
    Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of apomorphine in movement disorders.
    Colosimo C; Merello M; Albanese A
    Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
    Carbone F; Djamshidian A; Seppi K; Poewe W
    CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Apomorphine in off state--clinical experience].
    Rudzińska M; Szczudlik A
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B; Domzał T
    Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External and implanted pumps for apomorphine infusion in parkinsonism.
    Pollak P; Benabid AL; Limousin P; Gervason CL; Jeanneau-Nicolle E
    Acta Neurochir Suppl (Wien); 1993; 58():48-52. PubMed ID: 8109301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
    Grandas F
    Expert Rev Neurother; 2013 Dec; 13(12):1343-53. PubMed ID: 24160681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine in the treatment of Parkinson's disease.
    Hagell P; Odin P
    J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?
    Muhiddin KA; Roche MT; Pearce VR
    Postgrad Med J; 1994 May; 70(823):344-6. PubMed ID: 8016004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of dopamine agonists in Parkinson's disease management.
    Montastruc JL; Rascol O; Senard JM
    Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine in dopaminergic therapy.
    Subramony JA
    Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.